Are KARD insiders buying or selling?

In the last 90 days, Kardigan (KARD) had 2 insider transactions. Track every executive trade, dollar amount, and date.

Which hedge funds own KARD?

See every hedge fund and asset manager holding Kardigan (KARD).

How much of KARD trades in dark pools?

Track Kardigan (KARD) dark pool activity and off-exchange block trades.

Kardigan (KARD) Stock — 82.7% Short — Squeeze Watch

$14.79

+0.54 (+3.79%)

Weekly Expected Move ±9.1%

$12 $13 $15 $16 $17

NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 34 · $1.3B mcap · 50M float · 1.12% daily turnover · Short 83% of daily vol

Smart Money Score

Watch 25

Insider—

Congress—

ETF Holdings—

Key Statistics

Market Cap$1.3B

52W Range13.75-27

Volume524,433

Avg Volume562,133

Beta0.00

Dividend—

Analyst Ratings

1 Buy 0 Hold 0 Sell

Consensus Buy

Company Info

CEOTassos Gianakakos

Employees241

SectorHealthcare

IndustryBiotechnology

IPO Date2026-06-18

Websitekardigan.bio

506 Carnegie Center Drive
Princeton, NJ 08540
US

(415) 573-3220

About Kardigan, Inc.

Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its âCardiac Intelligenceâ platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.

Latest News